Funktionelle Magen-Darm-Erkrankungen

[1]  W. Chey,et al.  Randomised clinical trials: linaclotide phase 3 studies in IBS‐C – a prespecified further analysis based on European Medicines Agency‐specified endpoints , 2013, Alimentary pharmacology & therapeutics.

[2]  H. Feußner,et al.  [Diagnosis of oesophageal reflux by PH, impedance, and bilirubin measurement: recommendations of the German Society of Neurogastroenterology and of the working group for neurogastroenterology of the German Society for Digestive and Metabolic Diseases]. , 2012, Zeitschrift fur Gastroenterologie.

[3]  C. Pehl.  Funktionsdiagnostik (FD) in der stationären Gastroenterologie – Gap zwischen Bedarf und Bezahlung , 2012 .

[4]  Y. Li,et al.  Randomised clinical trial: an assessment of acupuncture on specific meridian or specific acupoint vs. sham acupuncture for treating functional dyspepsia , 2012, Alimentary pharmacology & therapeutics.

[5]  R. Stauber,et al.  Prognostic factors in patients with hepatocellular carcinoma treated with Sorafenib , 2011 .

[6]  J. Keller,et al.  S3-Leitlinie der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten (DGVS) und der Deutschen Gesellschaft für Neurogastroenterologie und Motilität (DGNM) zu Definition, Pathophysiologie, Diagnostik und Therapie intestinaler Motilitätsstörungen , 2011 .

[7]  G. Gerken,et al.  A 13-nation population survey of upper gastrointestinal symptoms : prevalence of symptoms and socioeconomic factors , 2011 .

[8]  P. Enck,et al.  [Irritable bowel syndrome: German consensus guidelines on definition, pathophysiology and management]. , 2011, Zeitschrift fur Gastroenterologie.

[9]  W. Chey,et al.  Rifaximin therapy for patients with irritable bowel syndrome without constipation. , 2011, The New England journal of medicine.

[10]  Yelena P. Wu,et al.  A pilot study to assess the efficacy of biofeedback-assisted relaxation training as an adjunct treatment for pediatric functional dyspepsia associated with duodenal eosinophilia. , 2010, Journal of pediatric psychology.

[11]  K. Gwee.  Post-Infectious Irritable Bowel Syndrome, an Inflammation-Immunological Model with Relevance for Other IBS and Functional Dyspepsia , 2010, Journal of neurogastroenterology and motility.

[12]  M. Fox,et al.  [Performance and interpretation of esophageal manometry: recommendations of the German Societies for Neurogastroenterology and Motility (DGNM), for Digestive and Metabolic Diseases (DGVS) and for General and Visceral Surgery (DGAV)]. , 2009, Zeitschrift fur Gastroenterologie.

[13]  K. Garsed,et al.  Postinfectious irritable bowel syndrome. , 2009, Gastroenterology.

[14]  A. Duggan,et al.  Clinical trial: a randomized trial of early endoscopy, Helicobacter pylori testing and empirical therapy for the management of dyspepsia in primary care , 2009, Alimentary pharmacology & therapeutics.

[15]  M. Camilleri,et al.  A placebo-controlled trial of prucalopride for severe chronic constipation. , 2008, The New England journal of medicine.

[16]  A. Salas,et al.  Systematic Evaluation of the Causes of Chronic Watery Diarrhea With Functional Characteristics , 2007, The American Journal of Gastroenterology.

[17]  R Jones,et al.  Guidelines on the irritable bowel syndrome: mechanisms and practical management , 2007, Gut.

[18]  J. Keller,et al.  Klinisch relevante Atemtests in der gastroenterologischen Diagnostik - Empfehlungen der Deutschen Gesellschaft für Neurogastroenterologie und Motilität sowie der Deutschen Gesellschaft für Verdauungs- und Stoffwechselerkrankungen , 2005 .

[19]  P. Whorwell,et al.  Long-term improvement in functional dyspepsia using hypnotherapy. , 2002, Gastroenterology.

[20]  M. Camilleri,et al.  Functional gastroduodenal disorders , 1999, Gut.

[21]  L. Melton,et al.  Onset and disappearance of gastrointestinal symptoms and functional gastrointestinal disorders. , 1992, American journal of epidemiology.

[22]  R. Spiller,et al.  FUNCTIONAL BOWEL DISORDERS , 2011 .